In the original article, there was a mistake in Table 2 as published. The item “NON prescription (C and Cbis)”, should have been listed as “NON prescription (C)”. Additionally, there was a mistake in Figure 1 as published. The horizontal axis interval was incorrect, therefore rendering the labels ineligible. The corrected Table 2 and Figure 1 appears below.
Table 2.
Market of switchable drugs (2015).
| Items | Switchable market | Overall market 2015 | % |
|---|---|---|---|
| Volumes (thousands of units) | 133,567 | 1,662,800 | 8.0% |
| Reimbursed prescription only (A) | 95,965 | 1,336,523 | 7.2% |
| NON Reimbursed prescription only (C) | 24,529 | 251,482 | 9.8% |
| NON prescription (C) | 13,073 | 74,795 | 17.5% |
| Expenditure (million Euro) | 1,677 | 15,979 | 10.5% |
| Reimbursed prescription only (A) | 1,198 | 12,295 | 9.7% |
| NON Reimbursed prescription only (C) | 316 | 3,038 | 10.4% |
| NON prescription (C) | 162 | 646 | 25.1% |
Source: own elaboration on IQVIA data.
Figure 1.
Market of switchable drugs by priority (2015). *Classified as OTC at least in 3 out of 4 main European Countries.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.